Söndag 22 December | 08:00:35 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-02-04 08:00 Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2024-05-21 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-06 - Bokslutskommuniké 2023
2023-11-21 - Kvartalsrapport 2023-Q3
2023-10-16 - Extra Bolagsstämma 2023
2023-08-22 - Kvartalsrapport 2023-Q2
2023-06-01 - X-dag ordinarie utdelning OSSD 0.00 SEK
2023-05-31 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OSSD 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-20 - X-dag ordinarie utdelning OSSD 0.00 SEK
2021-05-19 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-09 - Extra Bolagsstämma 2021
2021-02-11 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
OssDsign är verksamt inom läkemedelsbranschen. Bolaget är idag specialiserat inom forskning och utveckling av läkemedel för bendefekter. Läkemedlena baseras på biokeramiskt material vars sammansättning används för att förbättra läkningsprocessen i olika fall av patientskador. Produkterna vidaresäljs som implantat och används huvudsakligen för behandling av skallskador.
2024-04-02 07:00:00

Uppsala, Sweden, April 2 - OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing (GPO) agreement for Bone and Bone Substitute Implantable Products with Premier, Inc., a leading U.S. healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. The agreement is for a period of three years.

Effective July 1, 2024, the agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OssDsign's nanosynthetic bone graft OssDsign Catalyst[®].

"We are very pleased to have been awarded a long-term agreement with Premier for our innovative synthetic bone graft. It is a clear recognition of our market offering, and opens up a large, valuable network providing many more hospitals and patients access to OssDsign Catalyst," said Morten Henneveld, CEO, OssDsign.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. 12-month results from the clinical study TOP FUSION, published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.

Premier is a healthcare improvement company uniting an alliance of approximately 4,350 U.S. hospitals and health systems and more than 300,000 other providers and organizations. By providing integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.